English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

• Breast cancer is the most common cancer among women in South Korea. A total of 11,275 women were newly diagnosed as having breast cancer in 2006 and the agestandardized incidence rate per 100,000 was 35.5. (1) • Anastrozole and Letrozole are the third generation aromatase inhibitors, and they have been demonstrated to be more effective than tamoxifen as the first-line treatment for early breast cancer. • Anastrozole has shown more favorable disease-free survival (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.73-0.94; p=0.005) and a longer time to recurrence (HR, 0.74; 95% CI, 0.64-0.87; p=0.0002) versus tamoxifen on the completed treatment analysis of the ATAC trial, which was performed in postmenopausal women with early breast cancer. (3) Background

journal of breast cancer/journal of breast cancer

Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context